已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer

医学 乳腺癌 肿瘤科 内科学 癌症 新辅助治疗 事件(粒子物理) 残余物 风险评估 量子力学 算法 计算机安全 物理 计算机科学
作者
W. Fraser Symmans,Christina Yau,Yunn-Yi Chen,Ronald Balassanian,Molly Klein,Lajos Pusztai,Rita Nanda,Barbara A. Parker,Brian Datnow,Gregor Krings,Shi Wei,Michael D. Feldman,Xiuzhen Duan,Beiyun Chen,Husain Sattar,Laila Khazai,Jay Zeck,Sharon B. Sams,Paulette Mhawech‐Fauceglia,Mara H. Rendi
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:7 (11): 1654-1654 被引量:74
标识
DOI:10.1001/jamaoncol.2021.3690
摘要

Importance

Residual cancer burden (RCB) distributions may improve the interpretation of efficacy in neoadjuvant breast cancer trials.

Objective

To compare RCB distributions between randomized control and investigational treatments within subtypes of breast cancer and explore the relationship with survival.

Design, Setting, and Participants

The I-SPY2 is a multicenter, platform adaptive, randomized clinical trial in the US that compares, by subtype, investigational agents in combination with chemotherapy vs chemotherapy alone in adult women with stage 2/3 breast cancer at high risk of early recurrence. Investigational treatments graduated in a prespecified subtype if there was 85% or greater predicted probability of higher rate of pathologic complete response (pCR) in a confirmatory, 300-patient, 1:1 randomized, neoadjuvant trial in that subtype. Evaluation of a secondary end point was reported from the 10 investigational agents tested in the I-SPY2 trial from March 200 through 2016, and analyzed as of September 9, 2020. The analysis plan included modeling of RCB within subtypes defined by hormone receptor (HR) andERBB2 status and compared control treatments with investigational treatments that graduated and those that did not graduate.

Interventions

Neoadjuvant paclitaxel plus/minus 1 of several investigational agents for 12 weeks, then 12 weeks of cyclophosphamide/doxorubicin chemotherapy followed by surgery.

Main Outcomes and Measures

Residual cancer burden (pathological measure of residual disease) and event-free survival (EFS).

Results

A total of 938 women (mean [SD] age, 49 [11] years; 66 [7%] Asian, 103 [11%] Black, and 750 [80%] White individuals) from the first 10 investigational agents were included, with a median follow-up of 52 months (IQR, 29 months). Event-free survival worsened significantly per unit of RCB in every subtype of breast cancer (HR-positive/ERBB2-negative: hazard ratio [HZR], 1.75; 95% CI, 1.45-2.16; HR-positive/ERBB2-positive: HZR, 1.55; 95% CI, 1.18-2.05; HR-negative/ERBB2-positive: HZR, 2.39; 95% CI, 1.64-3.49; HR-negative/ERBB2-negative: HZR, 1.99; 95% CI, 1.71-2.31). Prognostic information from RCB was similar from treatments that graduated (HZR, 2.00; 95% CI, 1.57-2.55; 254 [27%]), did not graduate (HZR, 1.87; 95% CI, 1.61-2.17; 486 [52%]), or were control (HZR, 1.79; 95% CI, 1.42-2.26; 198 [21%]). Investigational treatments significantly lowered RCB in HR-negative/ERBB2-negative (graduated and nongraduated treatments) andERBB2-positive subtypes (graduated treatments), with improved EFS (HZR, 0.61; 95% CI, 0.41-0.93) in the exploratory analysis.

Conclusions and Relevance

In this randomized clinical trial, the prognostic significance of RCB was consistent regardless of subtype and treatment. Effective neoadjuvant treatments shifted the distribution of RCB in addition to increasing pCR rate and appeared to improve EFS. Using a standardized quantitative method to measure response advances the interpretation of efficacy.

Trial Registration

ClinicalTrials.gov Identifier:NCT01042379
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Beyond095完成签到 ,获得积分10
刚刚
从容成危完成签到,获得积分10
2秒前
yang完成签到 ,获得积分10
4秒前
聆琳完成签到 ,获得积分10
4秒前
5秒前
一个头两个大完成签到,获得积分10
5秒前
Kevin完成签到,获得积分10
5秒前
爆米花应助Grandir采纳,获得10
5秒前
不安愚志完成签到 ,获得积分10
6秒前
史前巨怪完成签到,获得积分10
6秒前
7秒前
科研达人发布了新的文献求助10
10秒前
传奇3应助简单山水采纳,获得10
10秒前
Milesgao完成签到,获得积分10
10秒前
悦耳冬萱完成签到 ,获得积分10
11秒前
郭京京完成签到 ,获得积分10
12秒前
上山石头完成签到,获得积分10
12秒前
kk完成签到 ,获得积分10
14秒前
可靠草丛完成签到,获得积分20
15秒前
ZZZ完成签到,获得积分10
17秒前
旷野完成签到,获得积分20
18秒前
20秒前
轻松的惜芹应助hellokitty采纳,获得10
20秒前
24秒前
28秒前
Lucky.完成签到 ,获得积分0
29秒前
陈陈完成签到,获得积分10
30秒前
31秒前
山鬼谣不会枯死的花完成签到,获得积分10
38秒前
半只熊完成签到 ,获得积分10
42秒前
45秒前
yangcy完成签到 ,获得积分10
46秒前
qinglongtsmc完成签到,获得积分10
47秒前
是小小李哇完成签到 ,获得积分10
52秒前
52秒前
future完成签到 ,获得积分10
53秒前
空白格完成签到 ,获得积分10
59秒前
1分钟前
椰小佳完成签到,获得积分20
1分钟前
美满的冬卉完成签到 ,获得积分10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989972
求助须知:如何正确求助?哪些是违规求助? 3532034
关于积分的说明 11256042
捐赠科研通 3270884
什么是DOI,文献DOI怎么找? 1805093
邀请新用户注册赠送积分活动 882256
科研通“疑难数据库(出版商)”最低求助积分说明 809216